Clinical Trials · NCT00635817
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Abbott
- Enrollment
- 84
- Start date
- Jun 2008
- Locations
- 25 sites, United States, Puerto Rico
- Primary endpoint
- Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6